In summary, these data demonstrate that in KRASG12C mutant lung cancer cells, targeting together RASG12C(ON) and SHP2 limits the development of adaptive resistance, which results in increased cancer cell apoptosis and tumour cell intrinsic IFN pathway responses. Here, PTPN11 is linked to neoplasm.